Abbott touts effective pain management, lower energy use in BurstDR SCS study results

Abbott (NYSE:ABT) late last week released results from a study of its BurstDR spinal cord stimulation technology, touting that it provided as effective pain relief as standard SCS despite providing lower-energy, intermittent stimulation known as “microdosing,” for patients with chronic intractable pain. Results from the BOLD study were presented at the 22nd Annual North American Neuromodulation Society Meeting in Las Vegas, the Chicago-area medtech company said. All patients in the BOLD trial reported experiencing pain relief with less than six hours of battery use per day while being treated with BurstDR, with 43% of patients reporting pain relief with less than two hours of battery use. Abbott said that data from the trial may indicate a potential strategy for prolonging SCS battery life while still maintaining optimal pain relief, and could improve the viability of recharge-free SCS devices. “While stimulation with BurstDR has been shown to provide superior efficacy compared to traditional stimulation in previous studies, battery consumption is an important consideration for physicians as we look to maximize the life of the devices for our patients and control their pain. This new data reinforces the benefits of BurstDR stimulation but also shows that microdosing BurstDR stimulation may help us extend device battery life for patients, which may help improve patient satisfaction with their SCS therapy,” primary investigator Dr. Timothy Deer of Charl...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Featured Neuromodulation/Neurostimulation Pain Management Spinal Abbott Source Type: news